Here are 1-3 brief analogies for Oncolytics Biotech (ONCY):

• A pre-revenue Amgen focused on cancer immunotherapy.
• A small Genentech developing novel cancer treatments.

• Pelareorep: An intravenously delivered immunotherapeutic agent developed for the treatment of solid tumors and hematological malignancies.

Oncolytics Biotech (ONCY) is a development-stage biopharmaceutical company. As such, it does not currently sell commercially approved pharmaceutical products directly to individuals (patients) or to institutions like hospitals or pharmacies.

Instead, its business model primarily revolves around the discovery, development, and eventual commercialization of drug candidates through collaborations and partnerships with larger pharmaceutical companies. In this context, the major "customers" or strategic partners that provide funding, resources, or future commercialization pathways are:

• Merck KGaA (Frankfurt Stock Exchange: MRK)
• Pfizer Inc. (NYSE: PFE)

Oncolytics Biotech has co-development agreements with both Merck KGaA and Pfizer Inc. for its lead product, pelareorep, indicating that these companies are key collaborators and effectively the primary "customers" or revenue-generating partners for a development-stage company like Oncolytics Biotech.

• Lonza Sales AG (parent company: Lonza Group AG, LONN.SW)
• AGM
• PrECOG LLC

Jared Kelly
Chief Executive Officer & Director

Jared Kelly was appointed Chief Executive Officer of Oncolytics Biotech in June 2025. He also serves as a Director on the company's board.

Kirk Look
Chief Financial Officer

Kirk Look is a Chartered Accountant with over two decades of experience in accounting, finance, tax, and treasury. He joined Oncolytics as the Company's Controller in April 2003 and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, Mr. Look was a Manager of Audit and Assurance Services with Ernst & Young LLP in Canada from 2000 to April 2003. He also held positions as Audit Manager and Senior Accountant at Ernst & Young LLP in Chile from 1998 to 1999. Mr. Look holds a Bachelor of Commerce from the University of Calgary and a Master of Science in Jurisprudence Law Degree from Seton Hall Law School.

Thomas C. Heineman, MD, PhD
Chief Medical Officer

Dr. Thomas C. Heineman serves as the Chief Medical Officer at Oncolytics Biotech.

Allison Hagerman, PEng, PMP, MBT
Chief Technology Officer

Allison Hagerman is the Chief Technology Officer at Oncolytics Biotech. She was also listed as Vice President, Product Development in 2024.

Andrew Aromando
Chief Business Officer

Andrew Aromando holds the position of Chief Business Officer at Oncolytics Biotech.

The key risks to Oncolytics Biotech's business (ONCY) are primarily centered around its financial viability and the successful development of its lead product.

1. Financial Stability and Need for Additional Financing: Oncolytics Biotech faces significant business risk due to uncertainty regarding its ability to continue as a going concern over the next twelve months. The company's survival is contingent upon securing additional financing through equity or strategic partnerships, as its current cash reserves are projected to sustain operations only until the third quarter of 2025. The challenges of raising capital in the micro-cap market and potential inability to further reduce expenditures exacerbate this risk, raising doubts about its long-term financial stability. As a pre-revenue company, it continues to incur substantial losses.
2. Clinical Trial Success and Regulatory Approval of Pelareorep: The company's entire valuation is tied to its lead immunotherapeutic agent, pelareorep. The success and timely completion of clinical studies and trials, as well as obtaining regulatory approval for pelareorep as a cancer treatment, are paramount. Any setbacks in clinical trials or mixed results, which have been observed in some instances with no definitive efficacy signals, could severely challenge the company's valuation. The company needs to advance pelareorep into registration-enabling studies.
3. Product Concentration: Oncolytics Biotech's business is highly dependent on the success of its single lead product, pelareorep. This single-asset focus means that transformative success could lead to significant returns, but a clinical failure of pelareorep would be catastrophic for the company's value, as it lacks a diversified pipeline to offset such a setback.

Oncolytics Biotech Inc.'s lead product, pelareorep, targets several significant addressable markets globally:

• Hematologic Malignancies: The global hematologic malignancies market was valued at approximately USD 65.1 billion in 2024 and is projected to reach USD 129.5 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 7.55% during 2025-2033. North America held the largest share of this market in 2024, accounting for 41%. Other sources estimate the global market at USD 77.5 billion in 2025, growing to USD 169.4 billion by 2035 at an 8.1% CAGR. Another report states a market size of USD 72.87 billion in 2024, expected to reach USD 147.38 billion by 2033 with an 8.14% CAGR.
• Solid Tumors: The global solid tumors market was valued at USD 362.21 billion in 2024 and is projected to reach USD 1,557.42 billion by 2032, with a CAGR of 20.00% during the forecast period of 2025 to 2032. North America dominates this market due to the rising prevalence of solid tumors and advancements in treatment. Other estimates indicate the solid tumor market size to be $232.2 billion in 2024, growing to $266.16 billion in 2025 at a CAGR of 14.6%, and further to $442.79 billion by 2029. Additionally, the global solid tumor therapeutics market reached USD 223.65 billion in 2026 and is forecast to reach USD 326.82 billion by 2031 at a 7.88% CAGR.
• Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): The global addressable market for mPDAC is approximately USD 3 billion, with a projected CAGR of 15% through 2032. This represents a global patient population of 500,000.
• Colorectal Cancer (CRC): Colorectal cancer affects 1.9 million patients worldwide and represents a global addressable market of USD 12.5 billion, with a 4.7% CAGR projected through 2033. For the specific subgroup of second-line (2L) KRAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), the annual total addressable market is estimated to be approximately USD 3-5 billion globally.
• Anal Cancer (Squamous Cell Anal Carcinoma - SCAC): Anal cancer impacts approximately 54,000 patients globally and represents a total addressable market of USD 1.01 billion, with an 8.7% CAGR projected through 2032.
• Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Metastatic Breast Cancer: This is described as a large patient population with substantial unmet medical need. While a specific global market size in USD was not explicitly found for this exact subset, the global metastatic breast cancer treatment market is expected to expand at a CAGR of 10.4% to reach $41.74 billion by 2030.

Oncolytics Biotech Inc. (ONCY), a development-stage biopharmaceutical company, anticipates its future revenue growth over the next 2-3 years to be primarily driven by the successful advancement and potential commercialization of its lead immunotherapeutic agent, pelareorep, across several key cancer indications. As the company currently generates no revenue from product sales, these drivers represent the pathways to initiating and growing its revenue stream.

The expected drivers of future revenue growth include:

1. Advancement and Potential Regulatory Approval of Pelareorep in HR-positive/HER2-negative Metastatic Breast Cancer: Pelareorep has demonstrated potential for accelerated approval in HR-positive, HER2-negative metastatic breast cancer, supported by efficacy data from the BRACELET-1 study. Oncolytics Biotech aims to initiate a registration-enabling study in this indication in the second half of 2024. Analysts project a substantial market opportunity, with potential annual sales estimated at $2.4 billion across the U.S. and major European markets by 2027, targeting approximately 55,000 addressable breast cancer patients.
2. Advancement and Potential Regulatory Approval of Pelareorep in KRAS-mutant MSS Metastatic Colorectal Cancer: The U.S. FDA granted Fast Track Designation for pelareorep in combination with bevacizumab and FOLFIRI for treating second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer in February 2026. Clinical data for this indication have shown a 33% objective response rate, significantly outperforming standard-of-care treatments which typically yield around 10%. The company plans to initiate a controlled clinical study in March 2026, with interim data expected by year-end 2026, targeting an estimated annual market of $3-5 billion for this specific patient population. The broader colorectal cancer market is projected to reach $20 billion by 2033.
3. Advancement and Potential Regulatory Approval of Pelareorep in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Pelareorep has shown promising clinical results in first-line pancreatic cancer studies and has received Fast Track and Orphan Drug designations from the FDA for mPDAC. Oncolytics Biotech is actively enrolling patients in the GOBLET Cohort 5 study for metastatic pancreatic cancer, supported by a $5 million grant. The company anticipates reporting initial efficacy results from this cohort by the end of 2024 and plans to initiate start-up activities for a registration-enabling study as early as Q4 2025.
4. Leveraging Strategic Co-development Agreements and Partnerships: Oncolytics Biotech has established a co-development agreement with Merck KGaA and Pfizer Inc. to advance pelareorep in combination with other therapies for HR-positive/HER2-negative metastatic breast cancer. The company emphasizes that its strategic focus on partnerships is crucial for extending its operational runway and unlocking significant shareholder value by progressing pelareorep toward regulatory registration and eventual commercialization.

Share Issuance

• In October 2025, Oncolytics Biotech entered into an at-the-market (ATM) equity financing agreement with BTIG, LLC, authorizing the company to sell up to $50 million in common stock.
• The company secured a $20 million share purchase agreement with Alumni Capital, announced in August 2025 (and finalized in April 2025), to provide flexible access to capital.
• Oncolytics Biotech's number of outstanding shares increased by 17.39% in one year, as of March 2026.

Inbound Investments

• By March 31, 2025, Oncolytics Biotech received a $5 million grant from the Pancreatic Cancer Action Network (PanCAN) to fund its GOBLET Cohort 5 study.

Capital Expenditures

• Capital expenditures for Oncolytics Biotech were recorded at -$9,333 in the last 12 months as of March 2026.
• Historical capital expenditures have also been very low, with figures such as -$174 million, -$6 million, -$42 million, -$228 million, and -$22 million (in Canadian dollars) reported across various periods.